Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 3 of 3
Full-Text Articles in Law
The Second Transformation Of The International Intellectual Property Regime, Peter K. Yu
The Second Transformation Of The International Intellectual Property Regime, Peter K. Yu
Faculty Scholarship
This chapter focuses on the structural changes that international investment norms have posed to the international intellectual property regime. It begins by documenting the regime’s first transformation by the adoption of the TRIPS Agreement and the marriage of intellectual property and trade through the World Trade Organization. The chapter then explores the regime’s potential second transformation when bilateral, regional, and plurilateral agreements and new investor-state disputes have caused international investment norms to intrude into the intellectual property domain. It continues to identify three sets of problems that have emerged from such intrusion. The chapter concludes by proposing three solutions to …
When The Chinese Intellectual Property System Hits 35, Peter K. Yu
When The Chinese Intellectual Property System Hits 35, Peter K. Yu
Faculty Scholarship
This article explores what it means for the Chinese intellectual property system to hit 35. It begins by briefly recapturing the system’s three phases of development. It discusses the system’s evolution from its birth all the way to the present. The article then explores three different meanings of a middle-aged Chinese intellectual property system – one for intellectual property reform, one for China, and one for the TRIPS Agreement and the global intellectual property community.
The Significance Of The Data Exclusivity And Its Impact On Generic Drugs, Srividhya Ragavan
The Significance Of The Data Exclusivity And Its Impact On Generic Drugs, Srividhya Ragavan
Faculty Scholarship
The following is a law review interview with Professor Srividhya Ragavan on the issues in interpretation of data exclusivity provisions under the TRIPS Agreement, and the impact of data exclusivity on generic drugs.